tiprankstipranks
Protagenic Therapeutics Regains Nasdaq Compliance, Boosts Confidence
Company Announcements

Protagenic Therapeutics Regains Nasdaq Compliance, Boosts Confidence

Protagenic Therapeutics (PTIX) has issued an announcement.

In a positive turn for investors, a company has successfully addressed its previous Nasdaq non-compliance issue by maintaining its stock price above the $1.00 minimum bid price for ten consecutive trading days. This accomplishment has resulted in the Nasdaq Listing Qualifications Department closing the deficiency notice, ensuring the company’s continued listing on the exchange and potentially restoring investor confidence in its financial stability.

For detailed information about PTIX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyProtagenic Therapeutics files $100M mixed securities shelf
TheFlyProtagenic announces safety data set from single-dose portion of Phase 1 trial
TheFlyProtagenic completes enrollment in single dose portion of Phase 1 trial
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Optimize your mobile reading experience. Download the TipRanks App today!